Invention Grant
- Patent Title: KCNQ2-5 channel activator
-
Application No.: US16059270Application Date: 2018-08-09
-
Publication No.: US10676438B2Publication Date: 2020-06-09
- Inventor: Kentaro Yashiro , Daisuke Wakamatsu , Tetsuji Saito
- Applicant: Ono Pharmaceutical Co., Ltd.
- Applicant Address: JP Osaka
- Assignee: Ono Pharmaceutical Co., Ltd.
- Current Assignee: Ono Pharmaceutical Co., Ltd.
- Current Assignee Address: JP Osaka
- Agency: Foley & Lardner LLP
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@3bfb3e81
- Main IPC: C07D213/61
- IPC: C07D213/61 ; A61K31/17 ; A61K31/341 ; A61K31/351 ; A61K31/381 ; A61K31/4045 ; A61K31/417 ; A61K31/422 ; A61K31/4245 ; A61K31/426 ; A61K31/435 ; A61K31/4545 ; A61K31/4965 ; A61K31/505 ; C07D213/74 ; C07D309/04 ; C07C275/32 ; C07C275/40 ; C07D333/20 ; C07D333/28 ; C07D413/06 ; C07C233/26 ; C07C233/29 ; C07D209/30 ; C07D213/40 ; C07D233/64 ; C07D239/26 ; C07D241/12 ; C07D271/06 ; C07D277/28 ; C07D307/52
Abstract:
The present invention relates to a compound represented by the general formula (I) (wherein the definition of each group has the same meaning as described in the specification). The compound is useful as preventive and/or therapeutic agent for KCNQ2-5 channel-related diseases.
Public/Granted literature
- US10570093B2 KCNQ2-5 channel activator Public/Granted day:2020-02-25
Information query
